Similarly, a large observational study in T2DM individuals (the FIELD study) showed that the use of a PPARα agonist (fenofibrate) did not reduce the risk of coronary events; however, it did reduce the total cardiovascular events, mainly due to fewer non-fatal myocardial infarctions and revascularizations [82], implicating that PPARα stimulation may have a beneficial effect in T2DM. The gene discussed is PPARA; the disease is myocardial infarction.